CTLA4 and neoplasm: We further extended this work to include an assessment of the impact of age on response to immune checkpoint blockade and here results were even more striking, with aged mice showing a greatly reduced anti-tumor effect of treatment with the combination of anti-PD-L1 and anti-CTLA-4 antibodies.